Reproductive Health Startup Raises $65M for Infertility Drugs

Reproductive health startup raises $65M for infertility drugs

Founded in 2021, ReproNovo has licensed rights to two drugs from Mereo BioPharma and ObsEva that it thinks could address fertility issues in men and women.

ReproNovo Raises $65M in Series A Financing

ReproNovo, a Lausanne, Switzerland-based company dedicated to developing treatments for reproductive medicine and women’s health, raised $65M in Series A funding. The round was led by Jeito Capital, co-led by AXA IM Alts and founding investor M Ventures, with participation from Ysios Capital and ALSA Ventures. The company intends to use the funds to advance […] The post ReproNovo Raises $65M in Series A Financing appeared first on FinSMEs.

Reproductive health biotech snags $65M to develop former Novartis and Merck KGaA drugs

A Swiss biotech has secured $65 million to launch a trio of mid-stage trials for two reproductive health drugs. ReproNovo announced the close of its Series A round on Wednesday. CEO Jean Marie Duvall co ...

Jeito, Axa IM Alts and the venture branch of the Merck KGaA laboratory support to the tune of $65 million ReproNovo, which tackles infertility and gynaecological diseases - two markets still poorly targeted by the pharmas.